Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
Gemcitabine is a deoxycytidine analogue that has a broad spectrum of antitumour activity in many solid tumours including pancreatic cancer. We have recently carried out a pharmacogenomic study in cancer patients treated with gemcitabine, and found that one genetic polymorphism of an enzyme involved in gemcitabine metabolism can cause interindividual variations in the pharmacokinetics and toxicity of this agent. In this paper, we review recent genetic studies of gemcitabine, and discuss the possibility of individualised cancer chemotherapy based on a pharmacogenomic approach.
Ueno
H
H
Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. hiueno@ncc.go.jp
Kiyosawa
K
K
Kaniwa
N
N
D000964:Antimetabolites, Antineoplastic / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004260:DNA Repair / Q000235:genetics; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D004798:Enzymes / Q000235:genetics; D023281:Genomics; D006801:Humans; D033703:Nucleoside Transport Proteins / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D004798:Enzymes; D033703:Nucleoside Transport Proteins; D003841:Deoxycytidine; D000093542:Gemcitabine